Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Year: 2020
Type: article
Abstract: Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49–72% at 6 months, 40–58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).
Source: Future Oncology
Authors: Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J Hanna, Jessica C Hassel, Felix Kiecker, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem, Matthias Hunger, Michael Schlichting, Mickaël Henry-Szatkowski, Sandra P D’Angelo
Institutions: Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Humboldt-Universität zu Berlin, ICON PLC (Ireland), Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Université de Lille, Centre Hospitalier Universitaire de Lille, Moffitt Cancer Center, European Institute of Oncology, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Fondazione IRCCS Istituto Nazionale dei Tumori, Dana-Farber Cancer Institute, Heidelberg University, University Hospital Heidelberg, University of Washington Medical Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3087335736